Stock Market News
Beximco buys stake in Bangladesh-based Nuvista for up to £18.3m
AIM-listed Beximco Pharmaceuticals has bought a majority stake in Bangladesh-based Nuvista Pharma, which specialises in hormones and steroid drugs, for up to £18.2m.
Beximco has entered into share purchase agreements with six shareholders with an aggregate shareholding of 85.2% in Nuvista.
The final consideration will paid in cash on completion of the acquisition, which is expected to occur on or before 28 February.
Nuvista was a subsidiary of Netherlands-based Organon International. It was sold to the current Bangladeshi management in 2006 and has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. The business has a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme.
In the year ended 30 June 2017, it generated revenue of 1.71bn Bangladeshi taka, pre-tax profit of 118m and had net assets 0.548bn.
Beximco's managing director, Nazmul Hassan, said: "The acquisition of a majority stake in Nuvista is an important milestone for Beximco Pharma, marking the first acquisition in the company's history. It further strengthens our strong market position with Nuvista's unique portfolio complementing our existing product range.
"The acquisition will serve as a strong foundation for sustainable future growth, as well as enhancing near-term revenue growth for the company."
At 1230 GMT, the shares were up 1.7% to 59.50p.
Beximco has entered into share purchase agreements with six shareholders with an aggregate shareholding of 85.2% in Nuvista.
The final consideration will paid in cash on completion of the acquisition, which is expected to occur on or before 28 February.
Nuvista was a subsidiary of Netherlands-based Organon International. It was sold to the current Bangladeshi management in 2006 and has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. The business has a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme.
In the year ended 30 June 2017, it generated revenue of 1.71bn Bangladeshi taka, pre-tax profit of 118m and had net assets 0.548bn.
Beximco's managing director, Nazmul Hassan, said: "The acquisition of a majority stake in Nuvista is an important milestone for Beximco Pharma, marking the first acquisition in the company's history. It further strengthens our strong market position with Nuvista's unique portfolio complementing our existing product range.
"The acquisition will serve as a strong foundation for sustainable future growth, as well as enhancing near-term revenue growth for the company."
At 1230 GMT, the shares were up 1.7% to 59.50p.
Related share prices |
---|
Beximco Pharmaceuticals Ltd. GDR (Reg S) (BXP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price